# AI Health Copilot Pro — Model Evaluation & Validation Report
**Author:** Dr. Harry Patria, Chief Data & AI Officer, Patria & Co.  
**Framework:** fullstack-analytics-builder + Agentic ML Integration (Chapter 10)  
**Dataset:** Pima Indians Diabetes Dataset (768 records, 8 clinical features)  
**Model Version:** 3.1.0 | **Evaluation Date:** October 2026

---

## 1. Executive Summary
Early detection of Type-2 diabetes risk allows proactive lifestyle and clinical intervention before irreversible metabolic complications arise. AI Health Copilot Pro combines:
1. **CRISP-DM Preprocessing Pipeline:** Explicit handling of biologically impossible zeros (converted to NaN) followed by median imputation (`SimpleImputer`) and standardization (`StandardScaler`).
2. **Predictive Modeling:** Stratified 80/20 train/test evaluation comparing Random Forest and Logistic Regression classifiers.
3. **Deterministic Physiological Flagging:** Hard-coded clinical cutoff validation prior to LLM reasoning.
4. **Agentic Explanation Layer:** Structured Gemini 3.8 Flash generation restricted strictly to observed flags and calibrated probability.
5. **ITDO Execution Framework:** Insight (probability) → Trigger (threshold alert ≥ 0.70) → Decision (clinical review) → Operation (Kanban intervention tasks).

---

## 2. Quantitative Model Performance (Holdout Test Set)

| Evaluation Metric | Target Threshold | RandomForest Model | Logistic Regression | Status |
| :--- | :--- | :--- | :--- | :--- |
| **AUC-ROC** | **≥ 0.8000** | **0.8354** | **0.8076** | **PASSED (Exceeds Target)** |
| **Accuracy** | ≥ 0.7500 | 0.7792 | 0.7273 | PASSED |
| **5-Fold Stratified CV AUC** | ≥ 0.8000 | 0.8280 (± 0.031) | 0.8012 (± 0.028) | PASSED |
| **Sensitivity (Recall Class 1)** | ≥ 0.6500 | 0.7037 | 0.5185 | PASSED |
| **Specificity (Class 0)** | ≥ 0.7500 | 0.8200 | 0.8400 | PASSED |

### Confusion Matrix (Test Set: N = 154)
- **True Positives (TP):** 38 (Correctly identified high-risk patients)
- **False Negatives (FN):** 16 (Under-predicted risk)
- **True Negatives (TN):** 82 (Correctly identified low-risk patients)
- **False Positives (FP):** 18 (Precautionary alerts)

---

## 3. Feature Importance & Physiological Drivers

| Rank | Feature | Importance Weight | Clinical Significance |
| :--- | :--- | :--- | :--- |
| **1** | **Glucose** | **33.4%** | Primary biomarker of impaired glucose tolerance / dysglycemia |
| **2** | **BMI** | **22.1%** | Adiposity index linked with peripheral insulin resistance |
| **3** | **Age** | **14.8%** | Progressive beta-cell decline and cumulative metabolic exposure |
| **4** | **DiabetesPedigreeFunction** | **11.2%** | Genetic susceptibility score |
| **5** | **Insulin** | **7.5%** | Marker of hyperinsulinemia and pancreatic compensation |
| **6** | **Pregnancies** | **4.9%** | Gestational metabolic stress |
| **7** | **BloodPressure** | **3.8%** | Vascular comorbidity indicator |
| **8** | **SkinThickness** | **2.3%** | Subcutaneous adiposity measurement |

---

## 4. Deterministic Clinical Ranges & Guardrails

```
- Fasting Glucose:      70 - 99 mg/dL     (Flagged if > 99: Prediabetes; > 125: Diabetes)
- Diastolic BP:         60 - 80 mmHg      (Flagged if > 80: Prehypertension; > 89: Stage 2)
- Body Mass Index:      18.5 - 24.9 kg/m² (Flagged if > 24.9: Overweight; ≥ 30.0: Obese)
- Age:                  0 - 120 years     (Flagged if ≥ 45: Screening guidelines)
- Serum Insulin:        < 166 μU/mL       (Flagged if > 166: Hyperinsulinemia)
```

---

## 5. CRISP-DM Verification Checklist
- [x] Phase 1: Ingestion & Zero-to-NaN conversion audit complete
- [x] Phase 2: EDA distribution and correlation analysis completed
- [x] Phase 3: Sklearn Pipeline with SimpleImputer + StandardScaler
- [x] Phase 4: Model comparison with 5-fold Stratified Cross-Validation
- [x] Phase 5: Comprehensive evaluation and normalized confusion matrix
- [x] Phase 6: Model serialization (`diabetes_model.sav`, `metrics.json`)
- [x] Phase 7: Deterministic flagging + Agentic LLM reasoning layer
